TFE3 translocation-associated PEComa is a distinct form of perivascular epithelioid cell neoplasm, the features of which are poorly defined owing to their general infrequency and limited prior reports with confirmed rearrangement or fusion. Recent investigation has found a lack of TSC gene mutation in these tumors compared with their nonrearranged counterparts, which underscores the importance of recognizing the translocated variant because of hypothetical ineffectiveness of targeted mTOR inhibitor therapy. Six cases were identified, and TFE3 rearrangement was confirmed by fluorescence in situ hybridization. Patient age ranged from 46 to 66 years (median 50 y), and none had a history of a tuberous sclerosis complex. Three cases arose in the uterine corpus, 1 in the vagina, 1 pelvic tumor, and 1 pulmonary tumor that was likely a recurrence/ metastasis from a probable uterine primary. Five cases had clear cell epithelioid morphology that showed a spectrum of atypia, while 1 case had a mixture of clear cell epithelioid and spindle cells. A mostly consistent immunophenotype was observed in the clear cell epithelioid cases: each demonstrated diffuse TFE3, HMB45, cathepsinK labeling, either focal or no melanA staining, and variably weak reactivity to smooth muscle markers. The mixed clear cell epithelioid and spindle cell case had a similar expression pattern in its epithelioid component but strong muscle marker positivity in its spindle cell component. Follow-up ranged from 1 to 57 months. Three cases demonstrated aggressive behavior, and 3 cases had no evidence of recurrence. Both GYN-specific and traditional sets of criteria for malignancy were evaluated. The GYN model showed improved inclusion and specificity in comparison to the traditional model.
A dvances in both light microscopic and molecular genetic studies have shown that a distinct subset of perivascular epithelioid cell neoplasm (PEComa) carries gene rearrangements involving TFE3 or transcription factor E3, a member of the MiTF-TFE family of transcription factors that assist in development of cells such as melanocytes. 1, 2 These tumors appear to have a unique morphology and a specific immunophenotype when compared to their conventional (nonrearranged) counterparts. 1, [3] [4] [5] [6] [7] They typically are composed of purely epithelioid cells with an alveolar architecture, mostly clear cytoplasm, and round nuclei and label strongly for TFE3 and HMB45. They minimally express muscle markers. Yet, a single reported TFE3-rearranged case has deviated from this pattern: it involved the urinary bladder of a 55-year-old woman and showed not just a biphasic pattern of clear cell epithelioid and spindle cells but also diffuse positivity for smooth muscle actin (SMA) and microphthalmia transcription factor (MiTF). 6 An explanation for this unusual case was a site-specific phenomenon or variations in the mechanism of gene fusion.
Conventional PEComa of either the sporadic or syndromic type frequently harbors mutation and loss of heterozygosity (LOH) of TSC2 and, much more rarely, TSC1. One investigation 8 found LOH involving the TSC2 locus in nearly two-thirds of their cases and LOH of TSC1 in only 1 case. The significance of LOH at TSC1/ 2 is the subsequent upregulation of mTOR signaling, which is the basis of mTORC1-targeted therapy that is often utilized in PEComa treatment. Recently, TFE3-rearranged tumors were shown to lack TSC2 inactivating mutations. 9 These findings have theoretically critical treatment implications, particularly for the efficacy of targeted mTOR inhibitors, as hypothetical benefit from this therapy is likely minimized. Therefore, recognition of the rearranged variant of PEComa may assist in important decisions for clinical management.
To date, reports of confirmed (either by fluorescence in situ hybridization [FISH] or reverse transcription polymerase chain reaction) TFE3-rearranged PEComa are few, with only 9 cases. 1, [3] [4] [5] [6] [7] The clinicopathologic findings in these cases suggest a mostly consistent morphology and immunoprofile, a disposition toward younger age, and no association with tuberous sclerosis complex (TSC). To better define the characteristics of TFE3-rearranged PEComa, we identified 6 cases originating in the gynecologic tract from our combined institutional archives, the largest series to date. We evaluated their morphologic and immunohistochemical (IHC) features, discuss differentiating these tumors from relevant morphologic mimics, compared recently proposed gynecologic tract-specific prognostic criteria 10 with previous criteria, 11 suggest a classification scheme for more consistent diagnosis and reporting, and review the literature's cases of translocation-associated PEComa occurring in any organ.
MATERIALS AND METHODS

Case Identification
The archives of Mayo Clinic's Department of Laboratory Medicine and Pathology and Memorial Sloan Kettering Cancer Center's Department of Pathology were searched for cases matching keywords "PEComa" or "perivascular epithelioid cell neoplasm" arising in any site of the gynecologic tract. From this cohort, a case was retrieved for review if mention was made of uniform TFE3 immunoexpression, extensive clear cell epithelioid morphology, HMB45 diffuse positivity, or negative reactivity to smooth muscle markers such as SMA, desmin, or h-caldesmon in the diagnostic report. Six cases with at least 1 of the aforementioned features were identified in total from both institutions. All available hematoxylin and eosin slides were examined. Formalin-fixed paraffinembedded tissue blocks were used for IHC and FISH studies. Clinical history, gross pathologic features, and patient follow-up data were obtained from institutional records or referring physicians.
Morphology
Each case was assessed for several morphologic features: pattern of invasion (infiltrative or carcinomalike; permeative or endometrial stromal sarcoma-like; pushing or invasion along a broad front), growth pattern, degree of cytologic atypia (determined as low or high grade), lymphovascular invasion, necrosis, multinucleated tumor cells, melanin-containing cells, and mitotic figures per 10 high-power fields (hpf) and per 50 hpf.
Immunohistochemistry
IHC was performed using an antibody panel consisting of TFE3 (clone MRQ-37; no dilution; Ventana Medical Systems, Tucson, AZ), HMB45 (clone HMB45; no dilution; Ventana), A103/MelanA (clone A103; no dilution; Ventana), SOX10 (polyclonal; 1:50 dilution; Cell Marque, Rocklin, CA), MiTF (clone D5; 1:50 dilution; Dako, Carpinteria, CA), cathepsinK (clone 3F9; dilution 1:500; Abcam, Cambridge, MA), SMA (clone a-sm-1; 1:50 dilution; Vector Laboratories, Burlingame, CA), desmin (clone DE-R-11; no dilution; Ventana), and h-caldesmon (clone E89; no dilution; Ventana). The Optiview or iView detection system (Ventana) was utilized for all antibodies with positive and negative controls as necessary.
Tumor cell immunoreactivity was semiquantitatively graded: 0 (negative); 1+ (1% to 25%); 2+ (26% to 50%); 3+ (51% to 75%); 4+ (> 75%). Tumor cell immunoreactivity was also semiqualitatively graded as weak (W) or strong (S). For calculation of IHC totals, a minimum score of 1+ with weak or strong staining was considered positive, with the exception of TFE3, wherein a 4+ and strong pattern was expected for a correlative TFE3 rearrangement.
Fluorescence In Situ Hybridization
FISH was performed on paraffin-embedded tissue sectioned at 4 mm thickness. Custom laboratory-developed probes designed to flank TFE3 were applied to interphase nuclei utilizing custom bacterial artificial chromosomes from the BACPAC Resources Center at Children's Hospital Oakland Research Institute (Oakland, CA). TFE3 hybridization set consisted of red 5 0 centromeric and green 3 0 telomeric probes as well as an aqua X centromere probe. A pattern of 2 yellow and 2 aqua signals indicative of normal or intact TFE3 is present on both X chromosomes. Balanced break-apart of TFE3 showed spatially split red and green signals resulting in a 1 red, 1 green, 1 fusion, and 2 aqua ratio per nucleus. A case was scored as positive if at least 10% of 100 scored nuclei showed a split signal pattern.
RESULTS
Clinical Findings and Patient Outcomes
Clinical features are summarized in Table 1 . The 6 patients ranged in age from 46 to 66 years (median 50 y). Three patients presented for clinical evaluation secondary to symptoms related to a uterine or pelvic mass. Two patients had their lesion discovered incidentally either by radiologic screening for an unrelated neoplasm or by microscopic assessment of a hysterectomy performed for symptomatic leiomyomata. The remaining patient developed hemoptysis as a consequence of an endobronchial mass. None had a history of TSC, and 1 patient had previously been treated by systemic chemotherapy for Hodgkin lymphoma 6 years preceding her PEComa diagnosis. Notably, 2 patients had undergone hysterectomy for symptomatic leiomyomata, both of which resulted in recurrence or metastasis. Three cases occurred in the uterine corpus, 1 in the vagina, 1 recurred in the pelvis from what was likely a consequence of pelvic seeding from uterine morcellation for leiomyomata, and the one removed from the lung was a probable metastasis from a lesion in her hysterectomy performed for leiomyomata given that this patient had no other oncologic history. The size of each tumor was highly variable, ranging from 1 to 17 cm (mean 6.5 cm, median 3.3 cm). Treatment depended on the site and size of the lesion. Total or eventual completion hysterectomy was required to achieve a negative margin for all corporeal tumors. Local excision resulted in positive margins for the vaginal primary. Likewise, in case 4, local resection of the pelvic mass was performed in addition to surgical staging. No patient had distant disease at the time of surgical intervention. However, recurrence or metastasis developed in 3 patients: 1 had regional recurrence involving the urinary bladder that was excised, another had a single metastasis to the lung removed by wedge resection, and the last patient had regional recurrence involving the cervix and metastases involving the omentum 2 months after her supracervical hysterectomy, followed 11 months later by adjuvant chemotherapy for extensive abdominopelvic disease, which was debulked. Importantly, this patient had a prior diagnosis of high-grade leiomyosarcoma until her intra-abdominal tumor showed features of PEComa. All available prior material was reviewed, and the morphology of each lesion was similar. Her adjuvant chemotherapy regimen was then switched from platinum based to mTORC1 targeted therapy. Follow-up information was available for all of the remaining 5 patients (case 6 was a recent case) and ranged from 1 to 57 months (mean 23 mo, median 17 mo). Every patient was alive without evidence of disease at their latest clinical examination.
Morphologic Features
Purely Clear Cell Epithelioid Morphology, Cases 1 to 5
Morphology findings are summarized in Table 2 . These 5 tumors showed entirely clear cell epithelioid morphology and a spectrum of cytologic features (Figs. 1, 2). All cases demonstrated some form of invasion, whether permeative, infiltrative, or pushing, into the surrounding myometrium or vaginal soft tissue, and a combination of invasion patterns was seen in some tumors. A nested growth pattern defined as a clustered or alveolus-like collection of cells partially encircled by either a thin-walled vessel and/or delicate collagenous stroma was maintained in every case (Figs. 1A-F). Diffuse, sheet-like growth was present in 1 tumor aside from other areas having the more usual nested appearance ( Fig. 1F ). There was variability in the degree of nuclear atypia. Low-grade atypia was observed in 3 cases and consisted of a uniform population of cells with welldefined, thin cell membranes, predominantly clear cytoplasm with some eosinophilic granularity, consistently round to somewhat ovoid nuclear shape, and a prominent small or medium single nucleolus (Figs. 1B-D). Highgrade atypia was noted in 2 cases and manifested as a range of cells with pleomorphism to frank anaplasia that maintained round nuclear membrane contours, clustered coarse chromatin, and large or multiple nucleoli (Figs. 1E, F). Dense to granular eosinophilic cytoplasm was present in these 2 cases along with the typical clear cytoplasm. Both lymphovascular invasion and necrosis were observed in 4 cases. Multinucleated tumor cells were seen in every case, and their atypia correlated with nu-clear atypia of the main neoplastic cells. Melanin-containing cells were found in 2 cases and comprised approximately 1% of the total cell volume ( Fig. 1B) . These cells showed accumulation of abundant intracytoplasmic melanin pigment and were intermixed and scattered throughout the tumors. Mitotic activity was present in 5 cases, mostly as low indices of 1 to 3/10 hpf or 2 to 5/50 hpf, but 1 case showed numerous figures up to 14/10 hpf or 66/50 hpf.
Mixed Clear Cell Epithelioid and Spindle Cell Morphology, Case 6
This case showed a mixed appearance consisting of spindle cells and epithelioid cells (Figs. 1G, H). The spindle cell form predominated as an estimated 70% of the tumor, whereas the epithelioid form was about 30%. The clear cell epithelioid cells were nearly identical to those in the purely epithelioid group with clear or somewhat eosinophilic cytoplasm, mostly uniform nuclear atypia, and a small to medium nucleolus. The spindle cell component had a fascicular growth consisting of cells with moderate amounts of eosinophilic to clear granular cytoplasm, hyperchromatic, enlarged nuclei with occasionally prominent nucleoli. Although thin-walled vessels were seen in the spindled portion, the cells were not encircled by them to create a nested or alveolar architecture that was seen in their epithelioid counterpart. Mitotic activity was 1/10 hpf and 2/50 hpf. Multinucleated tumor cells, necrosis, or melanin-containing cells were not identified.
Immunophenotypic Profile
Purely Clear Cell Epithelioid Morphology, Cases 1 to 5 IHC features are summarized in Table 3 . A mostly consistent immunophenotype was seen in all 5 cases. HMB45 and cathepsinK were strongly and diffusely expressed in every case (Figs. 1J, K). Nuclear TFE3 was equally strong and diffuse in 4 cases ( Fig. 1I ), but the 1 case with pleomorphic features (case 2) showed a weaker, but diffuse, pattern. MelanA was positive in a subset of cells in 2 tumors, whereas the other 3 tumors were The immunophenotype in this case differed from its purely epithelioid counterparts except for robust, uniform expression of TFE3 in all components. Although strong positivity for HMB45 was seen, it was confined to the epithelioid cell component. Similarly, melanA and MiTF were positive, strongly, but focally, in the epithelioid cell component. Both the epithelioid and spindle cell portions showed diffuse labeling by h-caldesmon with strong and focal expression of SMA in the spindle cells. Desmin and SOX10 were entirely negative.
TFE3 FISH Findings
FISH identified balanced TFE3 rearrangement in all 6 cases ( Fig. 1L ).
DISCUSSION
In 2002, Vang and Kempson 12 published a foundational study of gynecologic PEComa. In it, they examined a series of 8 cases of uterine PEComa to more fully define the clinical, morphologic, and IHC findings of these tumors and to refine features that improve recognition from smooth muscle tumors (SMT). One observation was that a subset of PEComa was purely epithelioid with a fairly uniform cytologic appearance, strong expression of HMB45, and negative or focal pos-itivity for melanA and muscle markers, all in keeping with what we now consider the TFE3-rearranged variant, whereas the remaining cases showed a combination of FIGURE 1. TFE3 translocation-associated PEComa typically shows a nested or alveolar architecture supported by thin-walled vascular spaces but has a spectrum of cytologic appearance. A, TFE3-rearranged tumors may show the typical PEC morphology of a cell with clear to granular eosinophilic cytoplasm, round to ovoid nucleus, and prominent nucleolus. B, These neoplasms tend to have a uniform appearance, and scattered melanin-containing cells are sometimes seen. C, Infiltration is routinely identified, in this case into the myometrium, although the cells have low-grade features and are associated with equally low-grade-appearing multinucleated tumor cells. D, Some tumors demonstrate extensively clear cytoplasm. E, High-grade features such as nuclear enlargement, prominent nucleoli, and marked pleomorphism are sometimes seen, but these tumors usually maintain their nested architecture. F, The mixed clear cell epithelioid and spindle cell rearranged case showed features of purely epithelioid tumors (G), but also had distinct areas of spindling and fascicular architecture (H). The expected immunophenotype of TFE3 translocationassociated PEComa is strong and diffuse TFE3 (I), HMB45 (J), and cathepsinK (K). L, TFE3 FISH consisted of red 5 0 centromeric and green 3 0 telomeric probes as well as an aqua X centromere probe. A pattern of 2 yellow and 2 aqua signals indicative of normal or intact TFE3 present on both X chromosomes. Balanced break-apart of TFE3 showed spatially split red and green signals resulting in a 1 red, 1 green, 1 fusion, and 2 aqua ratio per nucleus.
epithelioid and spindle cells with focal or scattered expression of HMB45 and strong positivity for muscle markers, all mostly in keeping with what we now consider the conventional variant. The inconsistency in this histologic-genetic correlation is the recently described mixed epithelioid and spindle cell TFE3-rearranged tumors. To date, only a single prior case has been reported. 6 Its IHC reactivity showed strong and diffuse HMB45 in the epithelioid component, as expected for a rearranged tumor, but then had unexpectedly strong and diffuse SMA in the spindle cell portion in addition to strong and diffuse MiTF in the epithelioid portion. Aside from this example, such an IHC profile has not been described in any other case with a confirmed rearrangement (Table 4 ). However, there is still a consistent pattern of morphology and IHC in the several forms of gynecologic PEComa that correlate very well with the presence of rearrangement and, importantly, probable lack of underlying TSC1 or TSC2 mutation. Our series of 6 TFE3-rearranged cases, 5 that are purely clear cell epithelioid with a range of cytologic atypia and 1 that is mixed clear cell epithelioid and spindle cell, exhibit a possible complete spectrum of these tumors. Review of literature's cases of confirmed TFE3-rearranged PEComa of any organ 1, [3] [4] [5] [6] [7] (Table 4) indicates that these neoplasms have an extreme predisposition to women (all 9 examples have occurred in women), no association with TSC, and a wide age spectrum (9 to 57 y, median 32 y). Our findings for gynecologic tumors are essentially identical. All 6 women had no history of TSC, but their age tended to be older (46 to 56 y, median 50 y). So far, including the present series, the total number of cases in the gynecologic tract is 6 in the uterine corpus, 1 in the ovary, and 1 in the vagina. However, this tally includes 2 patients in our series without an established diagnosis of gynecologic PEComa who underwent hysterectomy for symptomatic leiomyomata and had no other oncologic history. We believe this is explained by either a sampling issue, misrecognition, or, in the 1 case of uterine morcellation, seeding of the pelvic cavity. Additional support for these explanations is exemplified by the sometimes small size of these tumors. The smallest in our series was 1 cm. Gross size is just 1 of several important criteria recommended for evaluating a tumor for malignant potential.
Recently, gynecologic organ-specific criteria for malignancy were proposed 10 and were shown to be more inclusive and specific than traditional criteria. 11 Each system is outlined in Tables 5 and 6. The difference in the GYN model, which was developed after extensively assessing the pathologic features in 16 tumors of the female genital tract, is exclusion of invasion as a criterion (as it did not prove statistically significant in the prior analysis), increased threshold for a diagnosis of malignant PEComa (from 2 features to 4), and revision of "uncertain malignant potential" that was based on identifying either nuclear pleomorphism or multinucleated giant cells or a gross size Z5 cm and instead using this label for tumors that do not meet criteria for malig-nancy (or have 1 to 3 features). Both sets of criteria were applied to the present series, and an identical outcome of improved inclusion and specificity was seen when using the GYN model. Particularly, GYN-specific criteria correctly identified all cases that had shown aggressive behavior as malignant and labeling those without such an outcome as of uncertain malignant potential or benign. Although the traditional method also appropriately flagged the 3 malignant tumors in this series, it incorrectly classified 2 cases as malignant that have not shown any clinical evidence of recurrence. Further, 1 case could not be categorized as any prognostic type, because it showed only 1 feature that was not listed in the uncertain malignant potential grouping, hence the problem with inclusion. We believe this comparison of criteria systems again demonstrates improvement in classification by using GYN-specific criteria when evaluating any type of PEComa arising in the female genital tract. To date, after merging the literature's cases of TFE3 PEComa of any site with the present series of gynecologic TFE3 PEComa, 4 of 15 cases have shown aggressive behavior (Table 4 ). Properly diagnosing patients and offering the most accurate prognostic assessment of their tumor is obviously of significant clinic value. Accurate diagnosis of PEComa is more challenging in the female genital organs owing to its morphologic and IHC overlap with SMTs and other clear cell tumors. A definition of PEComa was recently proposed to aid in making this diagnosis 10 : in the appropriate cytologic context, demonstrating expression of 2 markers such as HMB45, melanA, or cathepsinK in addition to smooth muscle positivity. The utility of this definition comes in its recommendation of finding convincing positive staining for 2 melanocytic stains in the setting of a sometimes morphologically ambiguous spindle cell tumor (HMB45 and melanA are among the most tested stains, followed by cathepsinK with one report observing tyrosinase labeling 6 ). Demonstrating at least strong focal staining by 2 markers provides convincing evidence that the lesion in question is best regarded as PEComa since SMTs have been shown to label with HMB45 13 but not melanA. 10 Further, in the differential diagnosis of either PEComa or SMT, in most cases smooth muscle positivity is expected, and, therefore, IHC for this component is often omitted in our personal routine workup. We recommend a 3-stain panel for this differential consisting of HMB45, melanA, and TFE3. The pattern of these stains will discern all forms of PEComa and SMT accordingly: (1) TFE3-rearranged clear cell epithelioid PEComa shows a profile of marked and diffuse HMB45 and TFE3 expression and focal or negative melanA expression; (2) TFE3-rearranged mixed clear cell epithelioid and spindle cell PEComa shows a profile of marked expression of HMB45, melanA, and TFE3 in its epithelioid cells; (3) Conventional, nonrearranged PEComa shows a profile of patchy or focal expression of HMB45 and melanA and weak/negative expression of TFE3; (4) SMTs show a profile of patchy or negative HMB45 expression, negative melanA expression, and weak/negative TFE3. Gynecologic PEComa may be classified according to morphologic features, but we believe IHC is a useful and reliable adjunct to support its diagnosis. The distinct immunophenotype of each form of PEComa permits a simplified approach to diagnosis and, we believe, inherently structures a classification that provides more reproducibility in diagnosis and in reporting (Fig. 2) . It is important to recognize that the TFE3 protein is ubiquitously present at low levels, and weak labeling of this IHC stain is normal and not indicative of underlying rearrangement. 14 To this end, accurately assessing TFE3 immunoexpression can be difficult owing to significant differences in technique and staining platforms. 14 We recommend the use of TFE3 FISH in cases with equivocal qualitative (weak to moderate rather than strong and robust) or less than expected quantitative (< 90% of tumor cells) labeling in tumors otherwise morphologically and immunohistochemically appropriate for TFE3 PEComa. Further, this same immunopanel distinguishes translocation-associated PEComa from gynecologic clear cell morphologic mimics such as clear cell carcinoma and alveolar soft part sarcoma. Clear cell carcinoma shows no expression of TFE3, melanA, or HMB45. Alveolar soft part sarcoma, although diffusely and strongly positive for TFE3, is negative for HMB45 and melanA and harbors a unique ASPSCR1-TFE3 translocation, which has not been observed in any tested case of rearranged PEComa to date. Conventional PEComa displays a range of classic features of the perivascular epithelioid cell: clear to granular eosinophilic cytoplasm, round to ovoid nucleus, a prominent nucleolus, which clusters into nests or spindle into fascicles in differing proportions. The histologic features of this subtype are well described in prior reports. 10, 12, 15 Translocation-associated PEComa in gynecologic organs is currently recognized as involving the TFE3 gene. What is expected for a TFE3 gynecologic tumor is the more frequent pattern of nests or sheets of uniform epithelioid cells with mostly clear to slightly granular eosinophilic cytoplasm and small or large round or ovoid nucleus surrounded by a smooth nuclear membrane containing a single prominent nucleolus. Variations of this morphology include the pleomorphic (Fig. 1F ) and mixed clear cell epithelioid and spindle cell (Fig. 1G, H) forms, both of which are unusual manifestations of a tumor with an underlying rearrangement, because rearranged neoplasms tend to show consistency in their appearance. 1, 16 As such, PEComa is not the only tumor with TFE3 rearrangement. Alveolar soft part sarcoma (unbalanced ASPSCR1-TFE3), 17, 18 Xp11.2 renal cell carcinoma (balanced ASPSCR1-TFE3 among other fusion partner genes PRCC, PSF, CLTC, NONO), 19 and melanotic Xp11 neoplasm (TFE3 rearrangement with 1 case reported partnering with PSF) 20,21 resemble TFE3 PEComa in both their alveolar or nested architecture and clear or eosinophilic cytology, whereas the most recent member of the TFE3 tumor family, a subset of epithelioid hemangioendothelioma (YAP1-TFE3), 22 has entirely divergent features related to its vascular phenotype. Accordingly, it is likely that the mixed clear cell epithelioid and spindle cell and pleomorphic forms of these tumors are explained either by TFE3 fusing with different partners or undergoing breakage at different points along the gene.
Currently, a single case of translocated PEComa has demonstrated TFE3 partnering with PSF. 7 Subsequent evaluation by Argani et al 1 did not find PSF-TFE3 in 2 tested rearranged PEComa cases. Interestingly, PSF-TFE3 is the same fusion found in 1 case of melanotic Xp11 neoplasm, 21 a tumor with very similar morphology and often identical immunophenotype (the sole exception being patchy HMB45 in some cases rather than diffuse labeling) to TFE3-rearranged PEComa. 20, 21, 23 We identified scattered melanin-containing cells in 2 of our cases, but they comprised no greater than 1% the total cell volume, which contrasts their widespread distribution in melanotic Xp11 neoplasm. The significance, if any, of this histologic overlap is not yet known and may simply be a manifestation of their melanosomic nature.
Lastly, although some investigators may call into question the validity of assigning the name "PEComa" to these translocation-associated tumors, particularly because of their infrequent muscle marker expression, we believe it appropriate within the constraints of a morphologic and IHC study. It is increasingly recognized that the concept of PEComa as a "myomelanocytic tumor" has evolved to include a family of mesenchymal tumors, each with its range of clinical associations, morphology, immunophenotype, and genetic aberrations. The melanocytic properties of TFE3 translocated tumors are evident by their robust expression of melanosomic antibodies, HMB45, and tyrosinase (although experience with tyrosinase is limited) and sometimes focal expression of melanA. Even though muscle marker labeling by SMA, desmin, or h-caldesmon is uncommon, it is not negative and may possibly be underreported because of its focality. Some investigators have even proposed that demonstration of smooth muscle differentiation by IHC is not necessary, which is reflected in the definition found in the recent WHO classification of soft tissue 24 as well as our omission of muscle markers in our personal diagnostic workup.
In sum, we present the clinicopathologic findings of 6 cases of translocation-associated PEComa, TFE3 variant, arising in gynecologic organs. These tumors often have a distinct appearance and IHC features, which allow for their separation from conventional PEComa. Identification of translocation-associated PEComa may offer important clinical insight into behavioral potential and use of targeted therapeutic modalities. In addition, recently proposed GYN-specific prognostic criteria are more specific and inclusive than traditional criteria when evaluating either rearranged or conventional PEComa in the female genital tract.
